Huajian Medical and Chuangsheng Group signed a US$1.5 billion innovative drug pipeline asset RWA tokenization strategic cooperation agreement

According to Foresight News, Hong Kong-listed company Huajian Medical issued an announcement stating that its company and its subsidiary ETHK Inc and ETHK HOLDINGS LIMITED signed a US$1.5 billion strategic cooperation agreement with Chuangsheng Group Pharmaceuticals Co., Ltd. and its subsidiary Transcenta Oncology Inc. on the tokenization of potential innovative drug pipeline assets RWA.
Disclaimer: The views in this article only represent the author's personal views and do not constitute investment advice of this platform. This platform does not make any guarantees for the accuracy, completeness, originality and timeliness of article information, nor is it liable for any losses caused by the use or trust in article information.